Instil Bio, Inc. Net Income
Instil Bio, Inc. (TIL) reported Net Income of -$4.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-13
- Instil Bio, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$4.30M.
- Instil Bio, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$4.20M.
- Instil Bio, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$8.19M.
- Instil Bio, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$13.59M.
- Instil Bio, Inc. net income (loss) attributable to parent for fiscal 2025 was -$71.37M.
- Instil Bio, Inc. net income (loss) attributable to parent for fiscal 2024 was -$74.14M.
- Instil Bio, Inc. net income (loss) attributable to parent for fiscal 2023 was -$156.09M.
- Instil Bio, Inc. net income (loss) attributable to parent for fiscal 2022 was -$223.18M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.30M 10-Q · filed 2026-08-13 | -$8.50M 10-Q · filed 2026-08-13 | -$16.69M derived: sum of 3 quarters · filed 2026-08-13 | -$30.28M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$4.20M 10-Q · filed 2026-08-13 | -$12.39M derived: sum of 2 quarters · filed 2026-08-13 | -$25.98M derived: sum of 3 quarters · filed 2026-08-13 | -$47.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$8.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$21.78M derived: sum of 2 quarters · filed 2026-03-27 | -$43.17M derived: sum of 3 quarters · filed 2026-08-13 | -$71.37M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$13.59M 10-Q · filed 2025-11-13 | -$34.98M derived: sum of 2 quarters · filed 2026-08-13 | -$63.18M 10-Q · filed 2025-11-13 | -$75.08M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$21.39M 10-Q · filed 2026-08-13 | -$49.59M 10-Q · filed 2026-08-13 | -$61.49M derived: sum of 3 quarters · filed 2026-08-13 | -$84.51M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$28.20M 10-Q · filed 2026-08-13 | -$40.09M derived: sum of 2 quarters · filed 2026-08-13 | -$63.12M derived: sum of 3 quarters · filed 2026-08-13 | -$78.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2024-12-31 | -$11.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$34.92M derived: sum of 2 quarters · filed 2026-03-27 | -$49.83M derived: sum of 3 quarters · filed 2026-03-27 | -$74.14M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$23.02M 10-Q · filed 2025-11-13 | -$37.94M derived: sum of 2 quarters · filed 2025-11-13 | -$62.24M 10-Q · filed 2025-11-13 | -$75.17M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$14.92M 10-Q · filed 2025-11-13 | -$39.22M 10-Q · filed 2025-08-13 | -$52.14M derived: sum of 3 quarters · filed 2025-11-13 | -$119.58M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-03-31 | -$24.30M 10-Q · filed 2025-11-13 | -$37.23M derived: sum of 2 quarters · filed 2025-11-13 | -$104.66M derived: sum of 3 quarters · filed 2025-11-13 | -$123.32M derived: sum of 4 quarters · filed 2025-11-13 |
| 2023-12-31 | -$12.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$80.36M derived: sum of 2 quarters · filed 2025-03-04 | -$99.02M derived: sum of 3 quarters · filed 2025-03-04 | -$156.09M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$67.43M 10-Q · filed 2024-11-13 | -$86.09M derived: sum of 2 quarters · filed 2024-11-13 | -$143.16M 10-Q · filed 2024-11-13 | -$197.01M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$18.66M 10-Q · filed 2024-11-13 | -$75.73M 10-Q · filed 2024-08-13 | -$129.57M derived: sum of 3 quarters · filed 2024-11-13 | -$185.80M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-03-31 | -$57.07M 10-Q · filed 2024-11-13 | -$110.91M derived: sum of 2 quarters · filed 2024-11-13 | -$167.14M derived: sum of 3 quarters · filed 2024-11-13 | -$226.13M derived: sum of 4 quarters · filed 2024-11-13 |
| 2022-12-31 | -$53.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$110.07M derived: sum of 2 quarters · filed 2024-03-21 | -$169.06M derived: sum of 3 quarters · filed 2024-03-21 | -$223.18M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$56.22M 10-Q · filed 2023-11-13 | -$115.22M derived: sum of 2 quarters · filed 2023-11-13 | -$169.33M 10-Q · filed 2023-11-13 | -$224.68M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$58.99M 10-Q · filed 2023-11-13 | -$113.11M 10-Q · filed 2023-08-14 | -$168.46M derived: sum of 3 quarters · filed 2023-11-13 | -$211.46M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-03-31 | -$54.12M 10-Q · filed 2023-11-13 | -$109.47M derived: sum of 2 quarters · filed 2023-11-13 | -$152.47M derived: sum of 3 quarters · filed 2023-11-13 | -$187.78M derived: sum of 4 quarters · filed 2023-11-13 |
| 2021-12-31 | -$55.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$98.36M derived: sum of 2 quarters · filed 2023-03-31 | -$133.67M derived: sum of 3 quarters · filed 2023-03-31 | -$156.79M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$43.01M 10-Q · filed 2022-11-14 | -$78.32M derived: sum of 2 quarters · filed 2022-11-14 | -$101.44M 10-Q · filed 2022-11-14 | -$118.63M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$35.31M 10-Q · filed 2022-11-14 | -$58.44M 10-Q · filed 2022-08-12 | -$75.62M derived: sum of 3 quarters · filed 2022-11-14 | -$82.89M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-03-31 | -$23.13M 10-Q · filed 2022-11-14 | -$40.31M derived: sum of 2 quarters · filed 2022-11-14 | -$47.58M derived: sum of 3 quarters · filed 2022-11-14 | -$56.78M derived: sum of 4 quarters · filed 2022-11-14 |
| 2020-12-31 | -$17.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$24.45M derived: sum of 2 quarters · filed 2022-03-07 | -$33.65M derived: sum of 3 quarters · filed 2022-03-07 | -$37.74M 10-K · filed 2022-03-07 |
| 2020-09-30 | -$7.26M 10-Q · filed 2021-11-15 | -$16.46M derived: sum of 2 quarters · filed 2021-11-15 | -$20.55M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$9.20M 10-Q · filed 2021-11-15 | -$13.29M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$4.09M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |